Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share

(NYSE:INGR), WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company's common stock. The quarterly dividend will be payable on Jan. 20, 2026, to stockholders of record […]

Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share

Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share GlobeNewswire December 12, 2025 WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company's common stock. The quarterly

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NasdaqGM:CAMP), CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December

GRI Bio Announces Closing of $8.0 Million Public Offering

(NASDAQ:GRI), LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

(NASDAQ:AVXL), NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today provides an update on the

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

(NASDAQ:ALEC), SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO)

Navios Maritime Partners L.P. Announces Senior Leadership Changes

(NYSE:NMM), PIRAEUS, Greece, Dec. 12, 2025 (GLOBE NEWSWIRE) — Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry cargo and tanker vessels, today announced senior leadership changes. Angeliki Frangou, Chairwoman and Chief Executive Officer stated “Today marks the beginning of an exciting new chapter as we strengthen the executive

Amaze Announces Adjournment of Special Meeting of Stockholders

(NYSE MKT:AMZE), NEWPORT BEACH, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today announced that its Special Meeting of Stockholders, originally scheduled to be held on December 10, 2025, was convened and immediately adjourned due to the absence of a

ParaZero DefendAir Impresses German Bundeslander Police Leadership in Live Demonstration Organized by The Israeli Ministry of Defense

(NASDAQ:PRZO), Kfar Saba, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the successful demonstration of its advanced DefendAir counter-UAS (C-UAS) system at a high-profile event organized by

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NasdaqGM:TELA), MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common

Scroll to Top